MICHELE BURNS: Open Payments
NPI 1437248572 · SANTA ANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$958 in 41 payments from 13 companies in 2025. Trend: 2023 $579 · 2024 $395 · 2025 $958
Food & beverage: $958
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 7 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $141 |
| Vanda Pharmaceuticals Inc. | 6 | $140 |
| Otsuka America Pharmaceutical, Inc. | 5 | $138 |
| Neurocrine BioSciences, Inc. | 3 | $81 |
| ABBVIE INC. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Lilly USA, LLC | 1 | $31 |
| Novo Nordisk Inc | 1 | $26 |
| Alvogen Inc | 1 | $24 |
Products named: Korlym, CAPLYTA, FANAPT, REXULTI, INGREZZA, ABILIFY MAINTENA, AUSTEDO XR, LO LOESTRIN FE.
Industry payments across CA — which companies pay providers there.
